<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Trial id="240698"><TitleDisplay>Effect of a kind of fermented milk on metabolic syndrome in adolescents</TitleDisplay><TitleOfficial>Clinical trial on the effect of kind of fermented milk on cardiometabolic risk factors, insulin resistance, some incretin hormones and related immunological/inflammatory markers in 11 to 18-years-old adolescents with metabolic syndrome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201508081202N2</Identifier><Identifier type="Secondary Organisational">193059</Identifier></Identifiers><Indications><Indication id="3294">Metabolic syndrome X</Indication></Indications><BiomarkerNames><BiomarkerName id="38237" role="Therapeutic effect marker" type="Genomic;Proteomic">Incretins</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fermented camel milk</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fermented cow milk</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1040938" type="Company"><TargetEntity id="5035543127" type="organizationId">Isfahan University of Medical sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="3294" type="ciIndication"><TargetEntity id="E88.81" type="ICD10"/><TargetEntity id="10052066" type="MEDDRA"/><TargetEntity id="D024821" type="MeSH"/><TargetEntity id="-65628361" type="omicsDisease"/><TargetEntity id="512" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1040938">Isfahan University of medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>European Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2015-08-23T00:00:00Z</DateStart><DateChangeLast>2017-07-09T14:02:10Z</DateChangeLast><DateAdded>2015-09-23T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Isfahan University of Medical Sciences</Affiliation><Email>roya.kelishadi@gmail.com</Email><Name>Prof. Roya Kelishadi</Name><Phone>00983137923320</Phone></Contact><Contact type="Public contact"><Affiliation>Isfahan University of Medical Sciences</Affiliation><Email>z_fallah@mail.mui.ac.ir</Email><Name>Dr. Zahra Fallah</Name><Phone>00983137923321</Phone></Contact><Contact type="Public contact"><Affiliation>Isfahan University of Medical Sciences</Affiliation><Name>Dr. Zahra Fallah</Name><Phone>00983137923321</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 11 to 18 years old&lt;/li&gt;&lt;li&gt;Both genders&lt;/li&gt;&lt;li&gt;Iranian nationality&lt;/li&gt;&lt;li&gt;Diagnosed with metabolic syndrome major&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Other diseases&lt;/li&gt;&lt;li&gt;Not consuming milk product for &gt; 3 consecutive or 7 intermittent days&lt;/li&gt;&lt;li&gt;Side effects like allergic reactions&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Selected cardiometabolic risk factors: blood biochemistry and physical examinations</Description><Timeframe>During the week before and the week after 2 months intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Incretine hormones level: blood test</Description><Timeframe>During the week before and the week after 2 months intervention</Timeframe></Measure><Measure><Description>Insulin resistance level: blood test and calculation</Description><Timeframe>During the week before and the week after 2 months intervention</Timeframe></Measure><Measure><Description>Some immuno/inflammatory biomarkers: blood test</Description><Timeframe>During the week before and the week after 2 months intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to evaluate theeffect of different kind of fermented milk on cardiometabolic risk factors, insulin resistance, some incretin hormones and related immunological/inflammatory markers in 11 to 18-years-old adolescents with metabolic syndrome. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this triple-blind, randomized clinical trial, after obtaining parent's informed consent and subject's assent, eligible adolescents will be grouped into two arms using computerized block randomization (by sex and age group) (primary plan). The intervention will be 2 months consuming of fermented camel milk, 250 (500) cc daily with major meals. The control subjects will receive fermented cow milk with similar taste and appearance. Outcome variables will be checked during the week before and the week after 2 months intervention. A total of 3 days food record and physical activity questionnaire will be used at baseline. If the patient recruitment lasts too long, the parallel assignment will be changed to crossover. If good compliance is guaranteed, the amount of fermented milk will be raised to 500 cc daily.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Amin Hospital</Name><Address1>Isfahan</Address1><Contacts><Contact type="Facility contact"><Name>Dr. Zahra Fallah</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201508081202N2</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Metabolic syndrome X" id="20955"><Endpoint>Assessment of Metabolic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Metabolic syndrome X" id="20987"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Metabolic syndrome X" id="21017"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Metabolic syndrome X" id="21036"><Endpoint>Assessment of Cardiovascular Risk Factors</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Metabolic syndrome X" id="21087"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Metabolic syndrome X" id="20962"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Metabolic syndrome X" id="20952">Assessment of insulin resistance</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="20983"><Endpoint>Assessment of Incretins</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="20987"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="21003"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Metabolic syndrome X" id="32676"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Metabolic syndrome X" id="19348"><Criterion>Subjects with Metabolic Syndrome</Criterion></Inclusion><Inclusion disease="Metabolic syndrome X" id="19447"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Metabolic syndrome X" id="15492"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15530"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15535"><Criterion>Protocol Specific Exclusion Criteria for Females</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2015-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>3.29 Months</EnrollmentPeriod><EnrollmentRate>18.24 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-09-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-11-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial>